{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:17:37Z","timestamp":1772828257121,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xphs.2025.104019","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:24:09Z","timestamp":1760030649000},"page":"104019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of synergistic effects of \u03b2-defensin, vesatolimod and resiquimod in increasing the potency of a therapeutic HIV-1 vaccine candidate"],"prefix":"10.1016","volume":"115","author":[{"given":"Seyedeh Somayeh Hosseini","family":"Alarzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azam","family":"Bolhassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elnaz","family":"Agi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Nekouian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xphs.2025.104019_bib0001","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/v16030368","article-title":"Exploring HIV vaccine progress in the pre-clinical and clinical setting: from history to future prospects","volume":"16","author":"Kaur","year":"2024","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.xphs.2025.104019_bib0002","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/pathogens12020322","article-title":"Controversies in the design of strategies for the cure of HIV infection","volume":"12","author":"de Gea-Grela","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.xphs.2025.104019_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2023.12.006","article-title":"CD4+ T cell-targeting immunoliposomes for treatment of latent HIV reservoir","volume":"195","author":"Meeroekyai","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2025.104019_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1354502","article-title":"Dynamic modulation of the non-canonical NF-\u03bab signaling pathway for HIV shock and kill","volume":"14","author":"Chandrasekar","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.xphs.2025.104019_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010245","article-title":"The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription","volume":"18","author":"Okoye","year":"2022","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.xphs.2025.104019_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9874109","article-title":"The role of toll-like receptor signaling in the progression of heart failure","volume":"2018","author":"Yu","year":"2018","journal-title":"Mediat. Inflamm"},{"key":"10.1016\/j.xphs.2025.104019_bib0007","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fimmu.2020.01112","article-title":"The use of toll-like receptor agonists in HIV-1 cure strategies","volume":"11","author":"Martinsen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2025.104019_bib0008","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3389\/fmicb.2016.02152","article-title":"Unusual fusion proteins of HIV-1","volume":"7","author":"Langer","year":"2017","journal-title":"Front Microbiol"},{"issue":"11","key":"10.1016\/j.xphs.2025.104019_bib0009","doi-asserted-by":"crossref","first-page":"9320","DOI":"10.1007\/s12035-024-04173-w","article-title":"Transactivator of transcription (Tat)-induced neuroinflammation as a key pathway in neuronal dysfunction: a scoping review","volume":"61","author":"Muvenda","year":"2024","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.xphs.2025.104019_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00430-019-00583-z","article-title":"Genetic variation and function of the HIV-1 Tat protein","volume":"208","author":"Spector","year":"2019","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.xphs.2025.104019_bib0011","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.virol.2022.12.008","article-title":"Nef enhances HIV-1 replication and infectivity independently of SERINC5 in CEM T cells","volume":"578","author":"Ramirez","year":"2023","journal-title":"Virology"},{"key":"10.1016\/j.xphs.2025.104019_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110192","article-title":"Nef dimerization defect abrogates HIV viremia and associated immune disregulation in the Bone Marrow-Liver-Thymus-Spleen (BLTS) humanized mouse model","volume":"598","author":"Biradar","year":"2024","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.xphs.2025.104019_bib0013","article-title":"Engineered dendritic cells-derived exosomes harboring HIV-1 Nefmut-Tat fusion protein and heat shock protein 70: a promising HIV-1 safe vaccine candidate","volume":"270","author":"Pordanjani","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.xphs.2025.104019_bib0014","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.2147\/IJN.S131309","article-title":"Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation","volume":"12","author":"Di Bonito","year":"2017","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.xphs.2025.104019_bib0015","article-title":"Immunoinformatics analysis of potent therapeutic formulations for the development of HIV-1 Nefmut-carrying engineered exosomes","author":"Pordanjani","year":"2025","journal-title":"Curr HIV Res"},{"issue":"1","key":"10.1016\/j.xphs.2025.104019_bib0016","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/pathogens12010092","article-title":"Role of TLRs in HIV-1 infection and potential of TLR agonists in HIV-1 vaccine development and treatment strategies","volume":"12","author":"Rozman","year":"2023","journal-title":"Pathogens"},{"issue":"1","key":"10.1016\/j.xphs.2025.104019_bib0017","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"14","key":"10.1016\/j.xphs.2025.104019_bib0018","article-title":"TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview","volume":"21","author":"Kayesh","year":"2023","journal-title":"Front Microbiol"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2025.104019_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vetimm.2007.12.006","article-title":"Avian defensins","volume":"124","author":"van Dijk","year":"2008","journal-title":"Vet Immunol Immunopathol"},{"issue":"2","key":"10.1016\/j.xphs.2025.104019_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1574-695X.2009.00586.x","article-title":"Toll-like receptor-4 (TLR4) mediates human beta-defensin-2 (HBD-2) induction in response to Chlamydia pneumoniae in mononuclear cells","volume":"57","author":"Carratelli","year":"2009","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"11","key":"10.1016\/j.xphs.2025.104019_bib0021","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1093\/cid\/ciaa1534","article-title":"Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults living with human immunodeficiency virus-1","volume":"72","author":"Riddler","year":"2021","journal-title":"Clin. Infect. Dis"},{"key":"10.1016\/j.xphs.2025.104019_bib0022","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cyto.2017.06.006","article-title":"TLR7 and TLR8 agonist resiquimod (R848) differently regulates MIF expression in cells and organs","volume":"97","author":"Adzavon","year":"2017","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.xphs.2025.104019_bib0023","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/vaccines8030423","article-title":"Vaccine design from the ensemble of surface glycoprotein epitopes of SARS-CoV-2: an immunoinformatics approach","volume":"8","author":"Rahman","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.xphs.2025.104019_bib0024","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/bloodadvances.2023010821","article-title":"Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma","volume":"8","author":"Paiva","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.xphs.2025.104019_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10663","article-title":"Vaccine adjuvants for infectious disease in the clinic","volume":"9","author":"Goetz","year":"2024","journal-title":"Bioeng Transl Med"},{"issue":"2","key":"10.1016\/j.xphs.2025.104019_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10634","article-title":"Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations","volume":"9","author":"Hendy","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.xphs.2025.104019_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.756315","article-title":"Toll-like receptors as a therapeutic target in the era of immunotherapies","volume":"9","author":"Farooq","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.xphs.2025.104019_bib0028","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fimmu.2017.00407","article-title":"Immune responses to Bacillus Calmette-Gu\u00e9rin vaccination: why do they fail to protect against mycobacterium tuberculosis?","volume":"8","author":"Moliva","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2025.104019_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42888-3","article-title":"Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions","volume":"13","author":"Kopycinski","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.xphs.2025.104019_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350873","article-title":"Intestinal tissue-resident memory T cells maintain distinct identity from circulating memory T cells after in vitro restimulation","volume":"54","author":"Beumer-Chuwonpad","year":"2024","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.xphs.2025.104019_bib0031","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acscentsci.8b00823","article-title":"Linked toll-like receptor triagonists stimulate distinct, combination-dependent innate immune responses","volume":"5","author":"Albin","year":"2019","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.xphs.2025.104019_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1249718","article-title":"TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview","volume":"14","author":"Kayesh","year":"2023","journal-title":"Front Microbiol"},{"issue":"11","key":"10.1016\/j.xphs.2025.104019_bib0033","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1093\/cid\/ciaa1534","article-title":"Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults living with human immunodeficiency virus-1","volume":"72","author":"Riddler","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.xphs.2025.104019_bib0034","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2017.10.027","article-title":"Safety, efficacy, and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B","volume":"68","author":"Janssen","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.xphs.2025.104019_bib0035","article-title":"Surface immunogenic protein from Streptococcus agalactiae and Fissurella latimarginata hemocyanin are TLR4 ligands and activate MyD88- and TRIF dependent signaling pathways","volume":"14","author":"DA","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.xphs.2025.104019_bib0036","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/vaccines11050970","article-title":"Experimental medicine for HIV vaccine research and development","volume":"11","author":"Prudden","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"599","key":"10.1016\/j.xphs.2025.104019_bib0037","doi-asserted-by":"crossref","first-page":"eabg3071","DOI":"10.1126\/scitranslmed.abg3071","article-title":"The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy","volume":"13","author":"SenGupta","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xphs.2025.104019_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mib.2015.03.001","article-title":"Intracellular detection of viral nucleic acids","volume":"26","author":"Sparrer","year":"2015","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.xphs.2025.104019_bib0039","article-title":"Crosstalk between TLR8 and RIG-I-like receptors enhances antiviral immune responses","volume":"10","author":"Vlaming","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.xphs.2025.104019_bib0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ebiom.2017.09.028","article-title":"Cell-mediated immune predictors of vaccine effect on viral load and CD4 count in a phase 2 therapeutic HIV-1 vaccine clinical trial","volume":"24","author":"Huang","year":"2017","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.xphs.2025.104019_bib0041","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/v14050997","article-title":"Differences in expression of selected interleukins in HIV-infected subjects undergoing antiretroviral therapy","volume":"14","author":"Szyma\u0144ska","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.xphs.2025.104019_bib0042","first-page":"181","article-title":"Interferon gamma and soluble MICA as a new biomarker for immunological severity detection in HIV infected patients undergoing retroviral therapy","volume":"40","author":"Rareongjai","year":"2022","journal-title":"J. Health Sci. Med. Res"},{"key":"10.1016\/j.xphs.2025.104019_bib0043","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3389\/fimmu.2013.00498","article-title":"The significance of interferon-\u03b3 in HIV-1 pathogenesis, therapy, and prophylaxis","volume":"4","author":"Roff","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2025.104019_bib0044","first-page":"111","article-title":"Chronic inflammation in HIV pathogenesis: effects on immune cells, organ systems, and systemic consequences","author":"Lewis","year":"2019","journal-title":"Transl. Inflamm"},{"issue":"7","key":"10.1016\/j.xphs.2025.104019_bib0045","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/infdis\/jiu206","article-title":"Tumor necrosis factor \u03b1 is associated with viral control and early disease progression in patients with HIV type 1 infection","volume":"210","author":"Vaidya","year":"2014","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2025.104019_bib0046","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/imr.12823","article-title":"T-cell exhaustion in HIV infection","volume":"292","author":"Fenwick","year":"2019","journal-title":"Immunol Rev"},{"issue":"7","key":"10.1016\/j.xphs.2025.104019_bib0047","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/infdis\/jiad084","article-title":"Natural killer cell-derived interferon-\u03b3 regulates macrophage-mediated immunopathology during viral infection","volume":"228","author":"Feng","year":"2023","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2025.104019_bib0048","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.xphs.2025.104019_bib0049","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/v9040064","article-title":"Targeting TNF and TNF receptor pathway in HIV-1 infection: from immune activation to viral reservoirs","volume":"9","author":"Pasquereau","year":"2017","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.xphs.2025.104019_bib0050","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201745553","article-title":"Chemical and genetic control of ifn\u03b3-induced MHCII expression","volume":"19","author":"Wijdeven","year":"2018","journal-title":"EMBO Rep"},{"issue":"3","key":"10.1016\/j.xphs.2025.104019_bib0051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009363","article-title":"Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk","volume":"17","author":"Andersen-Nissen","year":"2021","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.xphs.2025.104019_bib0052","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.celrep.2017.11.075","article-title":"HIV-specific CD8+ T cells exhibit reduced and differentially regulated cytolytic activity in lymphoid tissue","volume":"21","author":"Reuter","year":"2017","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.xphs.2025.104019_bib0053","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1515\/bmc-2018-0007","article-title":"Interferon-gamma (IFN-\u03b3): exploring its implications in infectious diseases","volume":"9","author":"Kak","year":"2018","journal-title":"Biomol Concepts"},{"issue":"7","key":"10.1016\/j.xphs.2025.104019_bib0054","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1586\/14760584.2013.811208","article-title":"The use of toll-like receptor 7\/8 agonists as vaccine adjuvants","volume":"12","author":"Vasilakos","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"5663","key":"10.1016\/j.xphs.2025.104019_bib0055","first-page":"1526","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science (1979)"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:20:17Z","timestamp":1766582417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925004733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022354925004733"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104019","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of synergistic effects of \u03b2-defensin, vesatolimod and resiquimod in increasing the potency of a therapeutic HIV-1 vaccine candidate","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104019"}}